Serinus Biosciences
Powering drug development with cellular precision
Powering drug development with cellular precision
Serinus Biosciences is a biotechnology startup founded in 2022 with the slogan "Powering drug development with cellular precision." The company is focused on redefining precision in cancer therapeutics by designing models to determine how molecules function inside each tumor cell.
Through their knowledge-primed AI engine, which integrates computational biology and functional genomics, Serinus Biosciences aims to uncover the molecular landscape of treatment response or resistance. Their technology enables the development of drugs that work across a wide range of patient populations, override resistance mechanisms, and enable combinations by design.
The startup recently secured a $500.00K Pre Seed Round investment on 07 September 2022 from Y Combinator, signaling confidence from a notable investor in their innovative approach. As Serinus Biosciences continues to make strides in the biotechnology industry, their focus on cellular precision and therapeutic advancements positions them as a promising player in the field.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Pre Seed Round | $500.00K | 1 |
|
07 Sep 2022 |
No recent news or press coverage available for Serinus Biosciences.
We care about your data, and we'd love to use cookies make your experience better.